Primecap Management Co. CA Has $1.01 Billion Stake in Elanco Animal Health Incorporated $ELAN

Primecap Management Co. CA reduced its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 3.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,958,156 shares of the company’s stock after selling 1,808,658 shares during the quarter. Primecap Management Co. CA owned approximately 0.10% of Elanco Animal Health worth $1,006,157,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of ELAN. SJS Investment Consulting Inc. raised its position in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after buying an additional 951 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after buying an additional 2,414 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in Elanco Animal Health by 3,018.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after buying an additional 2,807 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Robert M. Vanhimbergen bought 6,950 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $21.64 per share, for a total transaction of $150,398.00. Following the completion of the acquisition, the chief financial officer owned 124,233 shares in the company, valued at approximately $2,688,402.12. This trade represents a 5.93% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev A. Modi purchased 4,500 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the transaction, the insider owned 123,082 shares of the company’s stock, valued at approximately $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 43,450 shares of company stock valued at $937,883. Insiders own 0.89% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $26.82 on Thursday. The firm has a fifty day moving average of $24.07 and a two-hundred day moving average of $21.66. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The stock has a market capitalization of $13.33 billion, a price-to-earnings ratio of -55.87, a PEG ratio of 3.92 and a beta of 1.87. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.14% and a negative net margin of 4.92%.The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the firm earned $0.14 earnings per share. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ELAN shares. UBS Group raised their price objective on shares of Elanco Animal Health from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Barclays started coverage on shares of Elanco Animal Health in a research note on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. Finally, Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health News Roundup

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 beat and upgraded FY‑2026 targets — Elanco reported Q4 revenue of $1.14B and adjusted EPS of $0.13 (above estimates), raised its FY‑2026 innovation revenue target to $1.15B and gave full‑year guidance for ~4%–6% organic growth and higher adjusted EBITDA/adjusted EPS targets. PR Newswire
• Positive Sentiment: Product launches driving innovation revenue — Management says all “Big 6” products are in market with Befrena approved in Q4, supporting the raised innovation revenue target and longer‑term growth thesis. MSN article
• Positive Sentiment: Analyst bullishness — KeyCorp and Leerink raised price targets (to $29 and $30 respectively) and maintained positive ratings, signaling dealer confidence in beat‑and‑raise execution. StreetInsider
• Positive Sentiment: Short interest fell sharply — Short interest dropped ~20.7% in February to ~18.4M shares (≈3.7% of float), lowering potential short‑squeeze risk and reducing downward pressure. (Days‑to‑cover ≈4.0 days).
• Neutral Sentiment: CEO visibility — Jeff Simmons appeared on CNBC with Jim Cramer, raising public visibility for the turnaround narrative; useful for sentiment but not a direct earnings lever. CNBC interview
• Neutral Sentiment: Earnings materials available — Call transcript and slides were published for investors to dig into segment trends and product cadence. Seeking Alpha transcript
• Negative Sentiment: Margin pressure flagged — Some coverage notes margins and cost trends prompted investor concern and caused shares to slip intra‑day despite the beat. That creates risk if GM/EBITDA margins remain under pressure. Investing.com
• Negative Sentiment: Mixed analyst view / limited near‑term upside — Morgan Stanley raised its target to $24 but kept an “equal weight” stance, implying limited upside (their PT sits below current levels), highlighting divergent analyst views on valuation. Benzinga
• Negative Sentiment: Q1 guidance slightly cautious — Q1 EPS guidance of $0.33–$0.36 is roughly in line but slightly below some consensus points, so near‑term beat risk is lower than for FY. (Company guidance details in the PR release above.)

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.